Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Gonadotropin releasing hormone analogue

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    18 result(s) found for: Gonadotropin releasing hormone analogue. Displaying page 1 of 1.
    EudraCT Number: 2010-020825-42 Sponsor Protocol Number: RTOG0815 Start Date*: 2010-11-08
    Sponsor Name:Radiation Therapy Oncology Group
    Full Title: A PHASE III PROSPECTIVE RANDOMIZED TRIAL OF DOSE-ESCALATED RADIOTHERAPY WITH OR WITHOUT SHORT-TERM ANDROGEN DEPRIVATION THERAPY FOR PATIENTS WITH INTERMEDIATE-RISK PROSTATE CANCER
    Medical condition: intermediate risk prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10026389 Malignant neoplasm of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001166-13 Sponsor Protocol Number: COU-AA-001 Start Date*: 2005-09-21
    Sponsor Name:Cougar Biotechnology, Inc
    Full Title: A Phase I/II Open Label Study of the 17α-hydroxylase/ C17,20 lyase inhibitor, Abiraterone acetate, in Patients with Prostate Cancer who have failed hormone therapy
    Medical condition: Hormone refractory prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    8.0 10062904
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-005431-86 Sponsor Protocol Number: FuTuRe Start Date*: 2014-02-10
    Sponsor Name:University Medical Center Groningen
    Full Title: Evaluation of 18F-FDHT PET/CT as an early treatment response marker in patients with metastasized castration-resistant prostate cancer to be treated with enzalutamide.
    Medical condition: Castration-resistant prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001626-17 Sponsor Protocol Number: CA209-9KD Start Date*: 2018-04-18
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2 Study of Nivolumab in Combination with Either Rucaparib, Docetaxel, or Enzalutamide in Men with Castration-resistant Metastatic Prostate Cancer
    Medical condition: Castration-resistant Metastatic Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) ES (Prematurely Ended) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020821-41 Sponsor Protocol Number: MDV3100-03 Start Date*: 2011-02-10
    Sponsor Name:Medivation, Inc., a wholly owned subsidiary of Pfizer Inc.
    Full Title: PREVAIL: A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naïve Patients with Progressive Metastatic Prostate Cancer W...
    Medical condition: Chemotherapy-Naïve Patients with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) NL (Completed) ES (Completed) SE (Completed) AT (Completed) FI (Completed) DK (Completed) SK (Completed) IT (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004213-13 Sponsor Protocol Number: ST101-101 Start Date*: 2020-07-13
    Sponsor Name:Sapience Therapeutics, Inc.
    Full Title: A phase 1-2 dose-escalation and expansion study of ST101 in patients with advanced unresectable and metastatic solid tumors
    Medical condition: Castrate-Resistant Prostate Cancer, HR Positive local advanced/metastatic Breast Cancer, Glioblastoma, and Melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-002249-13 Sponsor Protocol Number: 3125001 Start Date*: 2019-02-04
    Sponsor Name:Orion Corporation Orion Pharma
    Full Title: SAFETY AND PHARMACOKINETICS OF ODM-209 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER OR ESTROGEN RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED BRE...
    Medical condition: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER OR ESTROGEN RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10076506 Castration-resistant prostate cancer LLT
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DK (Completed) ES (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-001333-88 Sponsor Protocol Number: FP01C-17-001 Start Date*: 2017-08-23
    Sponsor Name:Foresee Pharmaceuticals Co., Ltd.
    Full Title: An Open-Label, Single-Arm Study of The Efficacy, Safety, and Pharmacokinetic Behavior of Leuprolide Mesylate Injectable Suspension (LMIS 25 mg) in Subjects with Prostate Cancer
    Medical condition: Prostate Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10036921 Prostate carcinoma LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: LT (Completed) SK (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2018-002011-10 Sponsor Protocol Number: D081SC00001 Start Date*: 2018-11-02
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration...
    Medical condition: Metastatic castration-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) CZ (Trial now transitioned) SK (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-004405-30 Sponsor Protocol Number: ARN-AR18-CT-102 Start Date*: 2014-02-12
    Sponsor Name:Arno Therapeutics Inc
    Full Title: A Phase 1 Study of Onapristone in Patients with Advanced Castration-resistant Prostate Cancer
    Medical condition: Advanced Castration-resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036920 Prostate cancer stage IV PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036911 Prostate cancer recurrent PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036910 Prostate cancer NOS LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066489 Progression of prostate cancer LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-001928-54 Sponsor Protocol Number: CA209-650 Start Date*: 2017-01-31
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2 Trial of Nivolumab Plus Ipilimumab in Men with Metastatic Castration-Resistant Prostate Cancer
    Medical condition: Metastatic Castration-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002534-23 Sponsor Protocol Number: 3124001 Start Date*: 2018-02-08
    Sponsor Name:Orion Corporation Orion Pharma
    Full Title: SAFETY AND PHARMACOKINETICS OF ODM-208 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Medical condition: Metastatic castration-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Trial now transitioned) FR (Trial now transitioned) GB (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2017-003552-23 Sponsor Protocol Number: 64091742PCR2002 Start Date*: 2018-05-10
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
    Medical condition: Metastatic castration-resistant prostate cancer (mCRPC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) BE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000149-34 Sponsor Protocol Number: CR845-310302 Start Date*: 2023-01-17
    Sponsor Name:Cara Therapeutics, Inc.
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled 12-Week Study to Evaluate the Safety and Efficacy of Oral Difelikefalin in Advanced Chronic Kidney Disease Subjects with Moderate-to-Seve...
    Medical condition: Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) PL (Prematurely Ended) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002030-36 Sponsor Protocol Number: CA2097DX Start Date*: 2019-11-26
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer
    Medical condition: Metastatic Castration-resistant Prostate Cancer (mCRPC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) DE (Completed) FR (Completed) BE (Completed) CZ (Completed) IT (Completed) RO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-001249-15 Sponsor Protocol Number: 314-12-401 Start Date*: 2013-11-07
    Sponsor Name:Otsuka Novel Products GmbH
    Full Title: A Two-Part Phase 1/2a, Open-Label, Dose-Escalation Study to Evaluate the Tolerability and Preliminary Antitumour Activity of OPB-111001 in Patients with Advanced Cancers that are Poorly Responsive ...
    Medical condition: • Advanced prostate cancer • Advanced epithelial ovarian cancer, advanced squamous cell carcinoma of the cervix, advanced breast cancer, endometrial cancer, and salivary gland cancer that are p...
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061934 Salivary gland cancer PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041848 Squamous cell carcinoma of the cervix PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-013174-41 Sponsor Protocol Number: CRPC2 Start Date*: 2009-10-14
    Sponsor Name:Medivation, Inc.
    Full Title: AFFIRM: A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Patients with Progressive Castration-Resistant Prostate Cancer Previously ...
    Medical condition: Patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed) GB (Completed) FR (Completed) ES (Completed) DE (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-005488-18 Sponsor Protocol Number: 8628-006 Start Date*: 2016-05-12
    Sponsor Name:Oncoethix GmbH, a wholly owned subsidiary of Merck Sharp & Dohme Corp.
    Full Title: A Phase IB Dose Exploration Trial with MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects with Selected Advanced Solid Tumors
    Medical condition: NUT Midline Carcinoma Non-Small Cell Lung Cancer Triple-Negative Breast Cancer Castration-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 28 12:28:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA